We applied deep targeted sequencing on 66 Chinese HCC samples and found that TERTp+/TP53+ could be used as a potential biomarker for predicting MVI‐positive patients and poor prognosis, laying a preliminary foundation for further exploration of co‐mutation in HCC with MVI and clinical treatment. This evidence concerns the gene TP53 and hepatocellular carcinoma.